Paper33099752
Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B.
Huang YW and 12 others. Hepatol Int, 2020. Cited by 26 papers, by iCite.
Cite this record
ConductScience Library. Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B. Papers, record 33099752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33099752
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hepatitis B, Chronic | Major topic |
| Interferon alpha-2 | Major topic |
| Antiviral Agents | |
| Hepatitis B Surface Antigens | |
| Hepatitis B e Antigens | |
| Humans | |
| Polyethylene Glycols | |
| Treatment Outcome |
Source PubMed
References2
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18613422 | Hepatitis B viral genotype in Taiwanese patients with acute hepatitis B. | Hepatogastroenterology | 2008 | https://conductscience.org/library/papers/18613422 | PubMed |
| 2 | 33383586 | CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018. | Clin Infect Dis | 2021 | https://conductscience.org/library/papers/33383586 | PubMed |
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42865026 | Safety, Tolerability and Antiviral Activity of GST-HG131 in Chronic Hepatitis B: A Randomized, Double-Blind Phase IIa Study. | Liver Int | 2026 | https://conductscience.org/library/papers/42865026 | PubMed |
| 41060606 | Emerging Significance and Implications of a Durable Complete Molecular Remission in the Treatment of Polycythemia Vera. | Curr Hematol Malig Rep | 2025 | https://conductscience.org/library/papers/41060606 | PubMed |
| 40637862 | A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA Adverse Event Reporting System (FAERS) database. | Ann Hematol | 2025 | https://conductscience.org/library/papers/40637862 | PubMed |
| 40335589 | Investigation into the pharmacodynamics and pharmacokinetics of recombinant human interferon alfa-2b vaginal suppository following process optimization in chinese rhesus macaque. | Sci Rep | 2025 | https://conductscience.org/library/papers/40335589 | PubMed |
| 40186764 | Sequential combination with ropeginterferon alfa-2b and anti-PD-1 treatment as adjuvant therapy in HBV-related HCC: a phase 1 dose escalation trial. | Hepatol Int | 2025 | https://conductscience.org/library/papers/40186764 | PubMed |
| 39935794 | Effect of HBeAg/anti-HBe coexistence on HBeAg seroconversion in treatment-naïve chronic hepatitis B patients with peginterferon-α. | Ther Adv Gastroenterol | 2025 | https://conductscience.org/library/papers/39935794 | PubMed |
| 39653378 | Site-Specific Glyco-Tagging of Native Proteins for the Development of Biologicals. | J Am Chem Soc | 2024 | https://conductscience.org/library/papers/39653378 | PubMed |
| 38771550 | A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19. | Infect Dis Ther | 2024 | https://conductscience.org/library/papers/38771550 | PubMed |
| 38644985 | Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment. | J Hematol | 2024 | https://conductscience.org/library/papers/38644985 | PubMed |
| 38399475 | Mouse Type-I Interferon-Mannosylated Albumin Fusion Protein for the Treatment of Chronic Hepatitis. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/38399475 | PubMed |
| 38203603 | Sequential Therapy with Ropeginterferon Alfa-2b and Anti-Programmed Cell Death 1 Antibody for Inhibiting the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma: From Animal Modeling to Phase I Clinical Results. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38203603 | PubMed |
| 38010606 | Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with Comorbidities. | Adv Ther | 2024 | https://conductscience.org/library/papers/38010606 | PubMed |
| 37182173 | An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1. | Front Oncol | 2023 | https://conductscience.org/library/papers/37182173 | PubMed |
| 36776307 | An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future. | Front Oncol | 2023 | https://conductscience.org/library/papers/36776307 | PubMed |
| 36519386 | Epidemiology, presentation, and therapeutic approaches for hepatitis D infections. | Expert Rev Anti Infect Ther | 2023 | https://conductscience.org/library/papers/36519386 | PubMed |
| 36406648 | A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C. | JGH Open | 2022 | https://conductscience.org/library/papers/36406648 | PubMed |
| 35746606 | Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis. | Viruses | 2022 | https://conductscience.org/library/papers/35746606 | PubMed |
| 34482769 | Hepatitis D virus (HDV): investigational therapeutic agents in clinical trials. | Expert Opin Investig Drugs | 2022 | https://conductscience.org/library/papers/34482769 | PubMed |
| 34386602 | Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy. | JGH Open | 2021 | https://conductscience.org/library/papers/34386602 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| IFNA1 | 3439 | PubTator's text mining | https://conductscience.org/library/genes/3439 | NCBI Gene |
| IFNA2 | 3440 | PubTator's text mining | https://conductscience.org/library/genes/3440 | NCBI Gene |
| KRT88P | 85348 | PubTator's text mining | https://conductscience.org/library/genes/85348 | NCBI Gene |
| SLC17A5 | 26503 | PubTator's text mining | https://conductscience.org/library/genes/26503 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33099752
GET https://conductscience.org/api/papers/v1/33099752/authors